Gerresheimer: Bormioli Pharma boosts revenues and earnings
Düsseldorf (ots) - - Revenues +11.6%, Adjusted EBITDA +13.1% - Organic development compared to pro forma figures Q1 2024: revenues -6.5%, adjusted EBITDA -9.3% - Q1 significantly influenced by revenue shift in syringe business - Guidance 2025 confirmed: organic revenue growth of 3-5% and adjusted EBITDA margin of 22% Gerresheimer, an innovative systems and solutions provider and global partner for the pharma, biotech and ...